000			05969cam a2200601Ii 4500
001			ocn913530203
003			OCoLC
005			20190328114812.0
006			m o d
007			cr cnu---unuuu
008			150709s2015 enk o 001 0 eng d
040			_aOPELS _beng _erda _epn _cOPELS _dKNOVL _dOCLCF _dEBLCP _dYDXCP _dZCU _dDEBSZ _dDXU _dYDX _dVGM _dOCLCQ _dS4S _dCOO _dU3W _dD6H _dRRP _dN$T _dMERER _dWYU _dOCLCQ
019			_a913694294 _a920816765 _a959423590
020			_a9780124172135 _q(electronic bk.)
020			_a012417213X _q(electronic bk.)
020			_z9780124172050
020			_z0124172059
035			_a(OCoLC)913530203 _z(OCoLC)913694294 _z(OCoLC)920816765 _z(OCoLC)959423590
050		4	_aRS403
060		4	_aQV 744
072		7	_aMED _x071000 _2bisacsh
082	0	4	_a615.1/9 _223
245	0	4	_aThe practice of medicinal chemistry / _h[electronic resource] _cedited by Camille Georges Wermuth, David Aldous, Pierre Raboisson, Didier Rognan.
250			_a4th ed.
264		1	_aLondon, UK : _bAcademic Press, _c2015.
300			_a1 online resource
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
520			_aThe Practice of Medicinal Chemistry, Fourth Edition, provides a practical and comprehensive overview of the daily issues facing pharmaceutical researchers and chemists. In addition to its thorough and excellent treatment of basic medicinal chemistry principles, this updated edition has been thoroughly revised to provide new and expanded coverage of the latest technologies and approaches in drug discovery. With in-depth coverage of high content screening, scoring, docking, binding free energy calculations, polypharmacology, QSAR, chemical collections and databases, and much more, this book is the go-to reference for all academic and pharmaceutical researchers who need a complete understanding of medicinal chemistry and its application to drug discovery and development.
500			_aIncludes index.
588	0		_aOnline resource; title from PDF title page (ScienceDirect, viewed July 9, 2015).
505	0		_aFront Cover; The Practice of Medicinal Chemistry; Copyright Page; Contents; List of Contributors; Foreword; Preface to the Fourth Edition; Preface to the Third Edition; Preface to the Second Edition; Preface to the First Edition; I. General Aspects of Medicinal Chemistry; 1 Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems; I. Definitions and Objectives; A Medicinal Chemistry and Related Disciplines and Terms; B Drugs and Drug Substances; C Stages of Drug Development; II. Drug Activity Phases; A The Pharmaceutical Phase.
505	8		_aB The Pharmacokinetic PhaseC The Pharmacodynamic Phase; D The Road to Successful Drug Development?; III. Drug Classification Systems; A Classification by Target and Mechanism of Action; 1 Targets; 2 Mechanisms of Action; B Other Classification Systems; References; 2 Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies; I. Introduction; II. Drug Discovery Approaches and Screening Cascades; A Target Based Screening; B Phenotypic Screening; III. In Vitro Assays; A Primary Assays; Glossary; 1 Binding assays; 2 Binding Studies: Principles and Analysis.
505	8		_a3 Enzyme Assays4 Types of Enzyme Inhibition and Their Analysis; A Reversible Inhibitors; B Irreversible Inhibitors; C Competitive Inhibitors; D Noncompetitive Inhibitors; E Uncompetitive Inhibitors; 5 Functional Assays; 6 Functional Studies and Their Analysis; A Agonist Concentration-Effect (E/[A]) Curves; B Full Agonists, Partial Agonists, and Inverse Agonists; C Optimizing Agonists; D Analysis of Antagonists; Competitive Antagonists; Irreversible, Noncompetitive, and Allosteric Antagonists; B Compound Interference in Primary Assays: Artifacts and False Positives; C Assay Biostatistics.
505	8		_aD Selectivity, Cytotoxicity, and Species Cross-over. 1 Selectivity; 2 Cytotoxicity; 3 Species Crossover; E Cellular and Tissue Functional Responses; IV. Ex Vivo Assays; V. In Vivo Assays; A Pharmacokinetic Models; B Efficacy Models; C Safety Testing; Acknowledgements; References; 3 Drug Targets, Target Identification, Validation, and Screening; I. Introduction; II. What is a Drug Target?; III. The Purpose of Target Identification; A Target-Based Screening; B Phenotypic Screening; C Fast Follower Strategy; IV. Target Options and Treatment Options; V. Target Deconvolution and Target Discovery.
505	8		_aVI. Methods for Target Identification and ValidationA Affinity Chromatography; B Genetic Methods; C Haploinsufficiency Profiling in Yeast; D Analysis of Resistant Mutants; E siRNA for Target Validation; F Yeast Three-Hybrid System; G DNA Microarrays; H Comparative Profiling; I Analysis of the Pathophysiology; J The Study of Existing Drugs; K Systems Biology; L In Silico Simulation of the Human Patient; VII. Target Validation; VIII. Conclusion; References; II. Lead Compound Discovery Strategies; 4 Strategies in the Search for New Lead Compounds or Original Working Hypotheses; I. Introduction.
504			_aIncludes bibliographical references and index.
588	0		_aPrint version record.
650		0	_aPharmaceutical chemistry.
650		0	_aDrugs _xDesign.
650		7	_aDrugs _xDesign. _2fast _0(OCoLC)fst00898790
650		7	_aPharmaceutical chemistry. _2fast _0(OCoLC)fst01060115
650		7	_aMEDICAL / Pharmacology. _2bisacsh
655		4	_aElectronic books.
655		0	_aElectronic books.
700	1		_aWermuth, C. G., _eeditor.
700	1		_aAldous, David _q(David John), _eeditor.
700	1		_aRaboisson, Pierre, _eeditor.
700	1		_aRognan, Didier, _eeditor.
776	0	8	_iPrint version: _tPractice of medicinal chemistry. _bFourth edition. _dLondon, UK : Academic Press, 2015 _z9780124172050
856	4	0	_3ScienceDirect _uhttp://www.sciencedirect.com/science/book/9780124172050
999			_c247114 _d247114